Neuroscience
From an AP report posted at Yahoo!:
Acadia Pharma Says Drug Study Encouraging
Wednesday June 22, 7:44 pm ET
Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall
SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc. on Wednesday said an ongoing mid-stage trial showed that its experimental drug did a better job than a placebo in reducing hallucinations and delusions in Parkinson's disease patients who suffer treatment-induced psychosis.
[snip]
Acadia said patients taking ACP-103 -- its lead drug candidate -- showed a greater reduction in psychotic symptoms than those taking a placebo, particularly lower hallucinations and delusions. The study involves 60 patients and the interim data came from an analysis of the first 30 patients to complete the trial. Acadia said no serious side effects were reported from ACP-103.
[ ... Read the full article ... ]~ From the Acadia website:
Anthony H. Risser | neuroscience | neuropsychology | brain
- Neuropsychology Abstract Of The Day: Scales To Measure Psychosis In Parkinson's Disease
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009 Dec; 15 Suppl 3, 38-341 Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Amgen's Gdnf And Parkinson Disease
From the AP, via The WashingtonPost.com website, concerning glial cell line-derived neurotrophic factor (GDNF): Autopsy Shows Parkinson's Drug's Progress By RANDOLPH E. SCHMID The Associated Press Friday, July 1, 2005; 3:57 PM WASHINGTON --...
- Issues In Clinical Trials: Gdnf And Parkinson Disease
Today's New York Times includes a front-page article about the culture of clinical-trials research: what happens to participant subjects when an experimental drug is pulled from testing and, among other issues, how teasing apart placebo-based from...
Neuroscience
Business World: Acadia Pharm, ACP-103, & Parkinson Disease
From an AP report posted at Yahoo!:
Acadia Pharma Says Drug Study Encouraging
Wednesday June 22, 7:44 pm ET
Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall
SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc. on Wednesday said an ongoing mid-stage trial showed that its experimental drug did a better job than a placebo in reducing hallucinations and delusions in Parkinson's disease patients who suffer treatment-induced psychosis.
[snip]
Acadia said patients taking ACP-103 -- its lead drug candidate -- showed a greater reduction in psychotic symptoms than those taking a placebo, particularly lower hallucinations and delusions. The study involves 60 patients and the interim data came from an analysis of the first 30 patients to complete the trial. Acadia said no serious side effects were reported from ACP-103.
[ ... Read the full article ... ]
" ACP-103, a proprietary small molecule discovered by ACADIA, is in development for treatment of the psychiatric and motoric dysfunction that frequently results from current Parkinson's disease therapies. ACP-103 is given orally and blocks the activity of the 5-HT2A receptor, a drug target that plays an important role in the treatment of various neuropsychiatric disorders."-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Neuropsychology Abstract Of The Day: Scales To Measure Psychosis In Parkinson's Disease
Goetz CG. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009 Dec; 15 Suppl 3, 38-341 Hallucinations and psychotic behaviors are a frequent non-motor aspect of Parkinson's disease and its treatment. These...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Amgen's Gdnf And Parkinson Disease
From the AP, via The WashingtonPost.com website, concerning glial cell line-derived neurotrophic factor (GDNF): Autopsy Shows Parkinson's Drug's Progress By RANDOLPH E. SCHMID The Associated Press Friday, July 1, 2005; 3:57 PM WASHINGTON --...
- Issues In Clinical Trials: Gdnf And Parkinson Disease
Today's New York Times includes a front-page article about the culture of clinical-trials research: what happens to participant subjects when an experimental drug is pulled from testing and, among other issues, how teasing apart placebo-based from...